{"id":675488,"date":"2023-11-06T18:14:01","date_gmt":"2023-11-06T18:14:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=675488"},"modified":"2023-11-06T18:14:01","modified_gmt":"2023-11-06T18:14:01","slug":"major-depressive-disorder-pipeline-clinical-trials-and-key-companies-gh-research-praxis-precision-medicines-abbvie-gedeon-richter-intracellular-therapies","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/major-depressive-disorder-pipeline-clinical-trials-and-key-companies-gh-research-praxis-precision-medicines-abbvie-gedeon-richter-intracellular-therapies_675488.html","title":{"rendered":"Major Depressive Disorder Pipeline | Clinical Trials and Key Companies &#8211; GH Research, Praxis Precision Medicines, AbbVie, Gedeon Richter, Intra-Cellular Therapies"},"content":{"rendered":"<div style=\"float:right; width:250px; padding:8px 10px 10px 10px;\">\n<div><a href=\"https:\/\/www.abnewswire.com\/uploads\/1585648587.jpeg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Major Depressive Disorder Pipeline | Clinical Trials and Key Companies - GH Research, Praxis Precision Medicines, AbbVie, Gedeon Richter, Intra-Cellular Therapies \" src=\"https:\/\/www.abnewswire.com\/uploads\/1585648587.jpeg\" alt=\"Major Depressive Disorder Pipeline | Clinical Trials and Key Companies - GH Research, Praxis Precision Medicines, AbbVie, Gedeon Richter, Intra-Cellular Therapies \" width=\"225\" height=\"225\" style=\"padding:0px 0px 10px 10px; border:0 solid !important;\" \/><\/a><\/div>\n<div class=\"quotes\">\n<div>DelveInsight Business Research LLP <\/div>\n<\/div>\n<\/div>\n<div style=\"font-style:italic; padding:8px 0px;\">DelveInsight\u2019s, \u201cMajor Depressive Disorder \u2013 Pipeline Insight, 2023,\u201d report provides comprehensive insights about 75+ companies and 75+ pipeline drugs in Major Depressive Disorder pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.<\/div>\n<p style=\"text-align: justify;\">DelveInsight&rsquo;s, &ldquo;<strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/major-depressive-disorder-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=dpr\">Major Depressive Disorder &ndash; Pipeline Insight, 2023<\/a><\/strong>,&rdquo; report provides comprehensive insights about 75+ companies and 75+ pipeline drugs in Major Depressive Disorder pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.<\/p>\n<p style=\"text-align: justify;\"><strong>Some of the Key Highlights&nbsp;<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>The key companies working in the major depressive disorder pipeline include GH Research, Praxis Precision Medicines, AbbVie, Gedeon Richter, Intra-Cellular Therapies, and many others.<\/li>\n<li>The Key Therapies working in major depressive disorder pipeline include SAGE-217, REL-1017, Seltorexant, SPL026, SP-624, PDC-1421 and many others&nbsp;<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>Got queries? Click here to learn more about the <\/strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/major-depressive-disorder-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=dpr\"><strong>Major Depressive Disorder Pipeline<\/strong>&nbsp;<\/a><\/p>\n<p style=\"text-align: justify;\"><strong>Major Depressive Disorder Overview<\/strong><\/p>\n<p style=\"text-align: justify;\">Major Depressive Disorder, also referred to as clinical depression, is a significant medical condition that can affect many areas of your life. It impacts mood and behavior as well as various physical functions, such as appetite and sleep. The exact cause of MDD isn&rsquo;t known. However, there are several factors that can increase the risk of developing the condition. Symptoms must occur for a period of 2 or more weeks and at least one symptom is either a depressed mood or loss of interest or pleasure. MDD is often treated with medication and psychotherapy. Some lifestyle adjustments can also help ease certain symptoms.<\/p>\n<p style=\"text-align: justify;\"><strong>DelveInsight&rsquo;s report covers around 75+ products under different phases of clinical development like<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Late-stage products (Phase III)<\/li>\n<li>Mid-stage products (Phase II)<\/li>\n<li>Early-stage product (Phase I) along with the details of<\/li>\n<li>Pre-clinical and Discovery stage candidates<\/li>\n<li>Discontinued and inactive candidates<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>Route of Administration<\/strong><\/p>\n<p style=\"text-align: justify;\">Major Depressive Disorder pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as<\/p>\n<ul style=\"text-align: justify;\">\n<li>Oral<\/li>\n<li>Subcutaneous<\/li>\n<li>Intravenous<\/li>\n<li>Intramuscular<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>Molecule Type<\/strong><\/p>\n<p style=\"text-align: justify;\">Products have been categorized under various Molecule types such as<\/p>\n<ul style=\"text-align: justify;\">\n<li>Bispecific Antibody<\/li>\n<li>Peptides<\/li>\n<li>Small molecule<\/li>\n<li>Gene therapy<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>Product Type<\/strong><\/p>\n<p style=\"text-align: justify;\">Drugs have been categorized under various product types like Mono, Combination, and Mono\/Combination.<\/p>\n<p style=\"text-align: justify;\">Learn more by requesting for sample @<strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/major-depressive-disorder-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=dpr\"> Major Depressive Disorder Pipeline&nbsp;<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Major Depressive Disorder Pipeline &nbsp;Key Companies&nbsp;&nbsp;<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>GH Research<\/li>\n<li>Praxis Precision Medicines<\/li>\n<li>AbbVie,&nbsp;<\/li>\n<li>Gedeon Richter<\/li>\n<li>Intra-Cellular Therapies&nbsp;<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">And many others&nbsp;<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Major Depressive Disorder Pipeline Therapies<\/strong>&nbsp;<\/p>\n<ul style=\"text-align: justify;\">\n<li>SAGE-217<\/li>\n<li>REL-1017<\/li>\n<li>&nbsp;Seltorexant<\/li>\n<li>SPL026<\/li>\n<li>&nbsp;SP-624<\/li>\n<li>PDC-1421&nbsp;<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">And many others&nbsp;<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Table of Contents<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Key Insights&nbsp;<\/li>\n<li>Report Introduction&nbsp;<\/li>\n<li>&nbsp;Executive Summary of Major Depressive Disorder Pipeline&nbsp;<\/li>\n<li>&nbsp;Disease Background and Overview<\/li>\n<li>&nbsp;Epidemiology and patient population<\/li>\n<li>&nbsp;Major Depressive Disorder Pipeline&nbsp; Emerging Therapies<\/li>\n<li>&nbsp;Major Depressive Disorder Pipeline &nbsp; Market Outlook<\/li>\n<li>Market Access and Reimbursement of Therapies<\/li>\n<li>&nbsp;Appendix<\/li>\n<li>Major Depressive Disorder Pipeline&nbsp; &nbsp; Report Methodology<\/li>\n<li>&nbsp;DelveInsight Capabilities<\/li>\n<li>Disclaimer<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">About DelveInsight<\/p>\n<p style=\"text-align: justify;\"><strong>Click here to read more about <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/major-depressive-disorder-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=dpr\">&nbsp;Major Depressive Disorder Pipeline&nbsp;&nbsp;<\/a><\/strong><\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Adya Kaul<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=major-depressive-disorder-pipeline-clinical-trials-and-key-companies-gh-research-praxis-precision-medicines-abbvie-gedeon-richter-intracellular-therapies\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> 919650213330<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Las Vegas<br \/><strong>State:<\/strong> Nevada<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/consulting\/due-diligence-services\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/consulting\/due-diligence-services<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/consulting\/due-diligence-services\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=major-depressive-disorder-pipeline-clinical-trials-and-key-companies-gh-research-praxis-precision-medicines-abbvie-gedeon-richter-intracellular-therapies\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>DelveInsight Business Research LLP DelveInsight\u2019s, \u201cMajor Depressive Disorder \u2013 Pipeline Insight, 2023,\u201d report provides comprehensive insights about 75+ companies and 75+ pipeline drugs in Major Depressive Disorder pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/major-depressive-disorder-pipeline-clinical-trials-and-key-companies-gh-research-praxis-precision-medicines-abbvie-gedeon-richter-intracellular-therapies_675488.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,405,417,406,404],"tags":[],"class_list":["post-675488","post","type-post","status-publish","format-standard","hentry","category-Business","category-Health-Medicine","category-Marketing-Sales","category-Pharmaceuticals-Biotech","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/675488","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=675488"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/675488\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=675488"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=675488"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=675488"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}